Fintel reports that on November 7, 2024, Cantor Fitzgerald upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from Neutral to Overweight.
Analyst Price Forecast Suggests 61.83% Upside
As of October 22, 2024, the average one-year price target for Sarepta Therapeutics is $194.88/share. The forecasts range from a low of $148.59 to a high of $231.00. The average price target represents an increase of 61.83% from its latest reported closing price of $120.42 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Sarepta Therapeutics is 2,022MM, an increase of 23.27%. The projected annual non-GAAP EPS is 2.68.
What is the Fund Sentiment?
There are 1,028 funds or institutions reporting positions in Sarepta Therapeutics. This is an increase of 119 owner(s) or 13.09% in the last quarter. Average portfolio weight of all funds dedicated to SRPT is 0.34%, an increase of 10.11%. Total shares owned by institutions increased in the last three months by 8.17% to 105,473K shares. 
The put/call ratio of SRPT is 0.63, indicating a bullish outlook.
What are Other Shareholders Doing?
Capital International Investors holds 4,321K shares representing 4.53% ownership of the company. In its prior filing, the firm reported owning 4,818K shares , representing a decrease of 11.50%. The firm increased its portfolio allocation in SRPT by 11.30% over the last quarter.
Janus Henderson Group holds 3,815K shares representing 4.00% ownership of the company. In its prior filing, the firm reported owning 4,891K shares , representing a decrease of 28.20%. The firm decreased its portfolio allocation in SRPT by 63.07% over the last quarter.
Avoro Capital Advisors holds 3,000K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 4,344K shares , representing a decrease of 44.81%. The firm decreased its portfolio allocation in SRPT by 3.77% over the last quarter.
IJH - iShares Core S&P Mid-Cap ETF holds 2,940K shares representing 3.08% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,851K shares representing 2.99% ownership of the company. In its prior filing, the firm reported owning 2,796K shares , representing an increase of 1.93%. The firm increased its portfolio allocation in SRPT by 21.01% over the last quarter.
Sarepta Therapeutics Background Information
(This description is provided by the company.)
Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
